Cedarburg Seeks to Bounce Back with New Offering

Privately owned process development and active pharma ingredient (API) manufacturer Cedarburg Pharmaceuticals (Grafton, WI) says it has been struggling in the highly competitive generic pharmaceuticals market and so is switching its focus toward the ethical pharma market, including projects for ‘virtual’ pharma and major pharma. The company tells CW that it recently raised $3.5 million from private investors and a debt offering to bolster this new direction. The funding will primarily be used to expand the firm’s capabilities in the virtual...

This information is only available to Chemical Week subscribers.

Forgot your user ID or password?
Click here to have it sent to you.

Email Address First Name Last Name

Not an IHS Chemical Week 24/7 member yet? Here's why you should be: Searchable online archive access of the last 2 years of Chemical Week. Print or digital magazine subscription Price and market change alerts Economic data and statistics Buyers' Guides Webcasts | whitepapers